Pubblicazioni

Autori:

Tamellini, E; Sorio, M; Andreini, A; Tecchio, C; Nadali, G; Bernardelli, A; Ferrarini, I; Crosera, L; Vatteroni, A; Simio, C; Benedetti, F; Krampera, M; Tanasi, I

Titolo:

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Blood Cell Therapy

N° Volume:

7

Numero o Fascicolo:

3

Intervallo pagine:

75-78

Parole chiave:

FLT3-inhibitors; acute myeloid leukemia; post-transplant relapse

Breve descrizione dei contenuti:

: Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.

Id prodotto:

141588

Handle IRIS:

11562/1141666

ultima modifica:

19 dicembre 2024

Citazione bibliografica:

Tamellini, E; Sorio, M; Andreini, A; Tecchio, C; Nadali, G; Bernardelli, A; Ferrarini, I; Crosera, L; Vatteroni, A; Simio, C; Benedetti, F; Krampera, M; Tanasi, I, Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia «Blood Cell Therapy» , vol. 7 , n. 3 , 2024 , pp. 75-78

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo